Literature DB >> 15042667

DNA repair and breast carcinoma susceptibility in women.

Juan M Ramos1, Abigail Ruiz, Rivka Colen, Ivette D Lopez, Lawrence Grossman, Jaime L Matta.   

Abstract

BACKGROUND: Breast carcinoma is the most common cancer and the second leading cause of cancer-related deaths among women. The disease represents approximately 31% of all cancers in Puerto Rican women. Several DNA repair pathways are involved in preventing carcinogenesis. The current study evaluated the hypothesis that a reduced DNA repair capacity (DRC) is a susceptibility factor for breast carcinoma.
METHODS: A retrospective case-control clinical study was performed to compare age-matched DRC in 33 women with histopathologically confirmed breast carcinoma (cases) and 47 cancer-free women (controls). DRC was measured using a host cell reactivation assay with a luciferase reporter gene and then transfected into human peripheral lymphocytes. A questionnaire was used to solicit breast carcinoma risk factors.
RESULTS: Women with breast carcinoma had a mean DRC of 5.6% +/- 0.5 standard error of the mean (SEM). Cancer cases had a 36% reduction (P<0.001) in DRC when compared with the control group (DRC=8.7% +/- 0.7 SEM). Younger participants with breast carcinoma were found to have a more significant reduction in DRC when compared with age-matched controls. Family (odds ratio [OR]=4.1), maternal lineage (OR=5.5), and maternal (OR=12.4) history of breast carcinoma were found to be the only statistically significant (P<0.05) risk factors associated with the disease.
CONCLUSIONS: The findings supported the hypothesis that a low DRC is a susceptibility factor for breast carcinoma. A 1% decrease in DRC corresponded to a 22% increase in breast carcinoma risk. To the authors' knowledge, the current study was the first to directly determine the DRC of women with breast carcinoma. Because DRC is an independent risk factor for breast carcinoma, the DRC of women may be a useful marker in predicting susceptibility. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042667     DOI: 10.1002/cncr.20135

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  43 in total

1.  Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.

Authors:  Tasha R Smith; Edward A Levine; Rita I Freimanis; Steven A Akman; Glenn O Allen; Kimberly N Hoang; Wen Liu-Mares; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2008-08-13       Impact factor: 4.944

2.  Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR.

Authors:  Nicola Machella; Mary Beth Terry; Jennifer Zipprich; Irina Gurvich; Yuyan Liao; Ruby T Senie; David O Kennedy; Regina M Santella
Journal:  Carcinogenesis       Date:  2008-06-19       Impact factor: 4.944

3.  Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Authors:  Tasha R Smith; Wen Liu-Mares; Beth O Van Emburgh; Edward A Levine; Glenn O Allen; Jeff W Hill; Isildinha M Reis; Laura A Kresty; Mark D Pegram; Mark S Miller; Jennifer J Hu
Journal:  Carcinogenesis       Date:  2011-06-23       Impact factor: 4.944

4.  Association between ERCC5 gene polymorphisms and breast cancer risk.

Authors:  Nari Na; Eer Dun; Lidong Ren; Guoxin Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Detection of DNA damage in peripheral blood mononuclear cells from pancreatic cancer patients.

Authors:  Rick J Jansen; Sharon Fonseca-Williams; William R Bamlet; Sylvette Ayala-Peña; Ann L Oberg; Gloria M Petersen; Carlos A Torres-Ramos
Journal:  Mol Carcinog       Date:  2014-08-11       Impact factor: 4.784

6.  Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research.

Authors:  Zachary D Nagel; Isaac A Chaim; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2014-04-26

7.  Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis.

Authors:  Zachary D Nagel; Carrie M Margulies; Isaac A Chaim; Siobhan K McRee; Patrizia Mazzucato; Anwaar Ahmad; Ryan P Abo; Vincent L Butty; Anthony L Forget; Leona D Samson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-22       Impact factor: 11.205

8.  Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients.

Authors:  Xuefeng Bai; Feng Jin; Yingzi Fu; Zhaojin Yu; Lin Zhao; Jie Ren; Yanlin Li; Xuyang Jiao; Haishan Zhao; Weifan Yao; Xiaoyi Mi; Enhua Wang; Olufunmilayo I Olopade; Mingyi Zhou; Minjie Wei
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

9.  Impact of EMS outreach: successful developments in Latin America.

Authors:  Ofelia A Olivero; Marcelo Larramendy; Sonia Soloneski; Carlos F M Menck; Jaime Matta; Gustavo A Folle; Enrique Zamorano-Ponce; Graciela Spivak
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

10.  Breast Cancer and DNA Repair Capacity: Association With Use of Multivitamin and Calcium Supplements.

Authors:  Yeidyly Vergne; Jaime Matta; Luisa Morales; Wanda Vargas; Carolina Alvarez-Garriga; Manuel Bayona
Journal:  Integr Med (Encinitas)       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.